Wellgistics Health Provides 2026 Corporate Outlook

Rhea-AI Summary

Wellgistics Health (NASDAQ:WGRX) provided its 2026 corporate outlook on January 7, 2026, announcing initial integration of its proprietary AI prescription optimization platform EinsteinRx into pharmacy point-of-sale systems and an onboarding target for its Wellgistics Pharmacy Network.

The company said it currently serves > 6,500 independent pharmacies, is optimizing onboarding to reduce friction, and aims to onboard up to 500 pharmacies per month by year-end 2026. Wellgistics plans to expand manufacturer relationships (starting with SGLT-2 drug Brenzavvy®) to cover diabetes, GLP-1/weight-loss and cardiometabolic patient groups. PharmacyChain™ smart-contract resource assessment is ongoing.

Positive

• EinsteinRx integration into POS systems has commenced
• Existing base of 6,500+ independent pharmacy customers
• Onboarding target of up to 500 pharmacies/month by year-end 2026
• Manufacturer relationship focus initiated (Brenzavvy® for diabetes)

Negative

• Onboarding process still being optimized; deployment speed not yet achieved
• PharmacyChain™ remains in resource assessment, not yet implemented
• Expansion relies on securing additional manufacturer relationships

Key Figures

Onboarding goal 500 pharmacies per month Target onboarding rate for Wellgistics Pharmacy Network by year end 2026

Existing customers 6,500+ pharmacies Independent pharmacy customers referenced for conversion into Wellgistics network

US diabetes market $48 billion Estimated 2024 US diabetes market size (iData Research)

US diabetes 2031 $79 billion Estimated 2031 US diabetes market size (iData Research)

GLP-1 market 2025 $53 billion Estimated 2025 North American GLP-1 agonist market (Grandview Research)

GLP-1 market 2030 $156 billion Estimated 2030 North American GLP-1 agonist market (Grandview Research)

Cardiometabolic 2024 $46 billion Estimated 2024 US cardiometabolic disorders market (Mobility Forsights)

Lost wages $170 billion annually Total US lost wages for 18M patients at over $9,000 per patient

Market Reality Check

$0.4052 Last Close

Volume Volume 157,567 is 0.38x the 20-day average 413,459, suggesting muted pre-news interest. low

Technical Shares at $0.42 are trading below the 200-day moving average of $1.53 and far under the $7.04 52-week high.

Peers on Argus

WGRX was up 1.18% pre-news, while peers showed mixed moves: PETS +7.53%, HKPD +9.5%, SSY +9.31%, versus declines in HITI -2.89% and SCNX -1.76%, indicating stock-specific dynamics rather than a clear sector trend.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 17	Meme coin reminder	Neutral	-7.1%	Reminder of Dream Bowl 2026 Meme Coin record date and distribution details.
Dec 08	Drug launch	Positive	+7.7%	Commercial launch of Brenzavvy® to 6,500+ independent pharmacies using EinsteinRx alerts.
Dec 04	Meme coin distribution	Positive	+7.0%	Announcement of 1-for-1 Dream Bowl 2026 Meme Coin distribution to shareholders.
Nov 26	Sponsorship & token	Positive	+14.8%	Dream Bowl 2026 sponsorship and participation in DataVault AI token distribution plan.
Nov 20	Earnings & update	Negative	-15.6%	Q3 2025 results showing large losses and highlighting EinsteinRx and Brenzavvy focus.

Pattern Detected

Stock generally moved in the same direction as the perceived tone of news, with positive commercial or promotional updates drawing gains and negative financials drawing losses, except for one promotional reminder that saw a selloff.

Recent Company History

Over the last few months, Wellgistics reported sharp losses and going-concern risks in its 10-Q and Q3 2025 results, while also restructuring its board and capital structure. It licensed PharmacyChain™ IP with multi‑year royalty obligations and sponsored the Dream Bowl 2026, tying in a meme coin distribution that previously drove double‑digit percentage gains. The Brenzavvy® launch to the 6,500+ pharmacy network also saw a positive reaction. Today’s 2026 outlook continues the EinsteinRx and PharmacyChain execution narrative against this financially stressed backdrop.

Market Pulse Summary

This announcement outlines Wellgistics’ 2026 focus on integrating its EinsteinRx AI into pharmacy point‑of‑sale systems and converting more of its 6,500+ independent pharmacies into a formal network, with a goal of onboarding up to 500 pharmacies per month by year end 2026. It also highlights ongoing PharmacyChain™ smart contract development. In context of prior heavy losses, auditor changes, and Nasdaq bid‑price deficiency, execution on these technology and onboarding milestones remains a key metric to monitor.

Key Terms

sglt-2 medical

"While SGLT-2 drug Brenzavvy® for the diabetes market is the first product that we are focused"

SGLT‑2 is a protein in the kidneys that acts like a gatekeeper, letting the body reclaim glucose from urine back into the bloodstream; drugs that block SGLT‑2 cause extra glucose to be flushed out through urine. It matters to investors because SGLT‑2 inhibitors are a major class of medicines for diabetes and related heart and kidney conditions, and new approvals, safety signals or expanded uses can quickly change a drug maker’s sales prospects and stock value.

glp-1 agonist medical

"including patients who have been prescribed GLP-1 agonist drugs and other drugs associated"

A GLP‑1 agonist is a drug that mimics a naturally occurring hormone involved in controlling blood sugar and appetite; think of it as a spare key that fits a body’s lock to trigger signals reducing blood sugar and slowing hunger. For investors, these medicines matter because they can treat common, long‑term conditions like diabetes and obesity, drive large prescription sales, and face close regulatory scrutiny and competitive innovation that affect company revenues and valuations.

cardiometabolic medical

"other drugs associated with cardiometabolic disease, such as Long COVID."

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

blockchain-enabled technical

"its patented blockchain-enabled smart contracts platform PharmacyChain™, today provided a"

A product, service, or process described as blockchain-enabled uses a tamper-resistant, shared digital record to store and verify transactions or data, so multiple parties can see the same information and changes are permanently recorded. For investors this matters because it can lower costs, reduce reliance on middlemen, and increase transparency and traceability—like replacing private ledgers with a public, auditable spreadsheet—while also bringing new operational and regulatory risks to weigh.

smart contracts technical

"end-to-end smart contracts to drastically reduce the administrative burden associated"

Self-executing digital agreements whose terms are written as code and stored on a distributed ledger so they run automatically when preset conditions are met — like a vending machine that releases a snack only after you insert the right coins. Investors care because smart contracts can speed up transactions, cut middlemen, reduce errors and fraud, and create new ways to issue, trade or enforce financial assets, which affects costs, risk and regulatory oversight.

AI-generated analysis. Not financial advice.

• Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy client point-of-sales systems has commenced

• EinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effort

• Company expects to onboard up to 500 pharmacies per month into formal Wellgistics Pharmacy Network by year end 2026

• Manufacturer supplier relationship expansion effort focused on diabetes, weight loss, cardiometabolic & Long COVID patients that existing pharmacy clients already serve

• PharmacyChain™ blockchain-enabled healthcare smart contract development resource assessment ongoing

TAMPA, FLORIDA / ACCESS Newswire / January 7, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence ('AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today provided a corporate outlook for 2026 to stakeholders.

"Three months following my return to the role of President at Wellgistics, the Company now has a clear direction as we begin a hyper-focused operational execution phase," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "In 2026 we will focus squarely on the implementation of our EinsteinRx™ AI platform into pharmacy client point of sale systems, onboarding and increasing the percentage of our existing 6,500+ independent pharmacy customers that convert into our official Wellgistics pharmacy network (the 'Wellgistics Pharmacy Network'). The key benefit for pharmacies enrolling in the Wellgistics Pharmacy Network will be the integration of patient-specific health information pulled from authorized provider databases with 'just-in-time' prescription optimization tools to empower our network's pharmacists to educate both providers and patients on the best personalized prescription drug selection and prescription drug-adjacent products & services that are associated with the best patient outcomes. We have already started the Wellgistics Pharmacy Network integration process with our closest pharmacy customers and are currently optimizing the onboarding process to make it as seamless as possible for pharmacists, leveraging client feedback to improve speed of deployment and reduce process friction. Once sufficiently optimized, we intend to accelerate the pharmacy conversion marketing effort as we also look to expand our prescription drug manufacturer supplier relationships. We have set a goal of reaching a Wellgistics Pharmacy Network onboarding rate of up to 500 pharmacies per month by year end 2026."

Mr. Patel continued, "While SGLT-2 drug Brenzavvy® for the diabetes market is the first product that we are focused on optimizing EinsteinRx for, we intend to quickly expand our branded manufacturer relationships to include other products that primarily target similar patient populations that make up a significant proportion of the patients Wellgistics Pharmacy Network pharmacies serve, including patients who have been prescribed GLP-1 agonist drugs and other drugs associated with cardiometabolic disease, such as Long COVID."

The US diabetes market was estimated to be $48 billion in 2024, growing to $79 billions by 2031 according to iData Research. The North American GLP-1 agonist market was estimated to be $53 billion in 2025, respected to grow to $156 billion by 2030 according to Grandview Research. The US cardiometabolic disorders market was estimated to be $46 billion in 2024, expected to grow to $85 billion by 2031 according to Mobility Forsights. Over 18 million patients in the United States lose an annual average of over $9,000 per patient, resulting in total lost wages estimated at over $170 billion annually according to research published in Nature Publication Journals Primary Care Respiratory Medicine.

"Concurrent with this onboarding optimization effort, our technology team has been working to complete its assessment of the resources required to establish PharmacyChain," added Mr. Patel. "We will very soon provide updates on this exciting effort that we expect will dramatically improve efficiency in the healthcare delivery market. PharmacyChain is being developed to implement end-to-end smart contracts to drastically reduce the administrative burden associated with optimal healthcare delivery, improve payer transparency and significantly increase the rate of timely insurance reimbursements for pharmacies, providers and other stakeholders in the United States while simultaneously rooting out fraud, waste and abuse in the healthcare system."

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains forward‑looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.'s and Wellgistics Health, Inc.'s filings with the SEC. Forward‑looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Wellgistics Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Wellgistics (WGRX) announce on January 7, 2026 about EinsteinRx?

Wellgistics said EinsteinRx integration into pharmacy point-of-sale systems has commenced to optimize prescription dispensing.

How many pharmacies does Wellgistics (WGRX) currently serve and what is the 2026 onboarding goal?

The company serves over 6,500 independent pharmacies and targets onboarding up to 500 pharmacies per month by year-end 2026.

Which drug categories is Wellgistics (WGRX) prioritizing for manufacturer relationships in 2026?

Wellgistics is prioritizing diabetes (including Brenzavvy®), GLP-1/weight-loss, cardiometabolic and Long COVID patient-focused products.

What is the status of Wellgistics' PharmacyChain™ smart contract project (WGRX)?

PharmacyChain™ is in a resource assessment phase and the company said it will provide updates once development resources are finalized.

Will EinsteinRx and PharmacyChain™ immediately change revenue guidance for Wellgistics (WGRX)?

The company did not provide revenue guidance or quantified financial impacts tied to EinsteinRx or PharmacyChain™ in the January 7, 2026 outlook.